Zydus infringed Takeda Pharma's patent : US court

Cadila Healthcare Ltd, a pharmaceutical company, has reported that net profit after taxes, minority interest and share of profit of assosciates for the fourth quarter ended March 31, 2013 was INR2.62 billion, or INR12.82 per share, compared to ...

Sushil Finance has recommended âBuyâ on Cadila Healthcare with target price of Rs 955 with low risk. Commenting on the investment rationale, the stock broker said, ''Cadila Healthcare (Cadila) reported decent set of numbers on the revenue front which were ...

Cadila Healthcare lost 0.41% to Rs 761.15 at 9:58 IST on BSE as the stock turned ex-dividend today, 11 June 2013, for interim dividend of Rs 7.50 per share for the year ended 31 March 2013. Meanwhile, the S&P BSE Sensex was down 86.91 points or ...

Mumbai: Cadila Healthcare Wednesday said it has received regulatory approval to market its diabetes drug, Lipaglyn, which it expects to clock over USD 1 billion sales a year when it is sold globally. The drug maker also said it is looking for ...

Biospectrum Singapore: Days after the Drug Controller General of India (DCGI) approved Cadila Healthcare's new chemical entity, Lipaglyn, for launch in India, the company announced its plans for the year 2020.Cadila Healthcare said in ...

The March quarter show of Cadila Healthcare was its best in eight quarters. A slowdown in the US business and under-performance of Zydus Wellness, the company's subsidiary engaged in the branded consumer products business, had impacted its ...

Cadila Healthcare chairman Pankaj Patel says firm is ready to take a calculated risk associated with

Cadila announced launch of its first NCE (New Chemical Entity) into domestic markets, which is likely to be marketed in India under the brand name of LIPAGLYN, which is the first Glitazar category drug to be approved in the world and is the first ...

Product launches in the US and stable domestic performance should help the company improve operating margins. June 8, 2013: A recovery in the US market on the back of new launches and steady performance in the domestic formulation business may hold Cadila ...